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Background: Cystic fibrosis (CF) lung disease begins in early life and is progressive with the major risk factor being
an exaggerated inflammatory response. Currently, assessment of neutrophilic inflammation in early cystic fibrosis
(CF) lung disease relies on bronchoalveolar lavage (BAL). The chitinase-like protein YKL-40 is raised in sputum and
serum of adults with CF. We investigated YKL-40 in BAL, serum and urine to determine whether this reflected
inflammation and infection in young children with CF.
Methods: YKL-40 was measured in matched samples of BAL, serum and urine obtained from 36 infants and
young children with CF participating in an early surveillance program. Levels were compared to clinical data
and markers of inflammation detected in the lung.
Results: YKL-40 in BAL correlated with pulmonary infection [β=1.30 (SE 0.34), p < 0.001] and BAL markers of
inflammation [macrophage number: r2 = 0.34, p < 0.001; neutrophil number: r2 = 0.74, p < 0.001; neutrophil
elastase: r2 = 0.47, p < 0.001; CXCL8: r2 = 0.45, p < 0.001; IL-β: r2 = 0.62, p < 0.001]. YKL-40 was detectable in
serum but levels did not correlate with BAL levels in the same individuals (r2 = 0.04, p = 0.14) or with inflammatory
markers. YKL-40 was below the limit of detection in urine (30 pg/ml).
Conclusions: This study demonstrates that levels of the chitinase-like protein YKL-40 reflect airway inflammation and
infection in early CF lung disease. The lack of increased YKL-40 in serum in the absence of systemic inflammation limits
the benefit of this potential biomarker in early disease.
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Cystic fibrosis (CF) is still the most common life-
limiting genetic disease in Caucasian populations. While
survival and quality of life have improved in the past de-
cades, the majority of children born with CF will still die
from progressive lung disease in early to mid-adulthood.
Lung disease may be present in infants within the first
weeks of life [1-3] with abnormalities reported in: lung
function [1,4]; pulmonary inflammation [2,5]; and infec-
tion, including with Pseudomonas aeruginosa [2,6]; and
changes on chest computed tomography (CT) consistent
with early onset bronchiectasis [2,3,7]. Once established,* Correspondence: p.sly@uq.edu.au
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unless otherwise stated.bronchiectasis is essentially irreversible [8] and progresses
to respiratory failure and death or the need for lung
transplantation in the majority of patients.
A growing body of evidence has demonstrated that the
major risk factors for both the initiation and progression
of bronchiectasis in early life include the presence of free
neutrophil elastase (NE) [3], infection and inflammation
[8]. The most reliable way of detecting pulmonary in-
flammation and infection in early life is by bronchoscopy
and bronchoalveolar lavage (BAL) [9]. However, these pro-
cedures are invasive and cannot be repeated frequently.
To overcome the limitations inherent in BAL-based
programs, biomarkers of infection and inflammation in
the lung are urgently needed. A number of biomarkers
have been proposed from studies in adults or older chil-
dren with established CF lung disease. These include thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of metalloproteinase-1 (TIMP-1) [11], and the elastin
breakdown products desmosine and isodesmosine [12].
YKL-40 (chitinase-3-like-1; CHI3L1), also known as
human cartilage glycoprotein 39 (HC gp-39), is a human
glycoprotein that binds to chitin, but does not possess
chitin hydrolase activity. YKL-40 is secreted by a variety
of cells, including neutrophils [13] and macrophages
[14] and expression is induced by IFN-γ [15] and release
stimulated by IL-6 [16]. Although the exact function is
unknown, it is associated with inflammation, extracellu-
lar tissue remodelling, fibrosis and solid carcinomas.
Serum YKL-40 has been investigated as a biomarker
[17] for cancer [18], osteoarthritis [19], cardiovascular
diseases [20] and a number of diseases involving inflam-
mation, tissue remodelling and fibrosis [21,22]. YKL-40
levels have been also associated with asthma, atopy and
other immune-related phenotypes [23,24]. Recently, in-
creased YKL-40 levels in sputum were found to correlate
with pulmonary function in adults with CF, suggesting
YKL-40 usefulness as potential biomarker in CF lung
disease [10]; increased levels were reported in sputum
and, to a lesser extent, in serum from adults with CF
compared to healthy control individuals. Thus, while not
specific to CF, YKL-40 has the potential to be a bio-
marker of inflammation in early CF lung disease.
However, biomarkers that appear to be useful in estab-
lished lung disease may not have the same value in early
CF disease [25,26]. This situation is exemplified by the
use of cyanide in respiratory secretions to indicate the
presence of infection with P. aeruginosa. As P. aeruginosa
is the only important cyanobacterium present in the lungs
of patients with CF, the detection of cyanide in sputum or
exhaled breath of patients with chronic P. aeruginosa
infection [27,28] appeared to be a promising biomarker.
However, when investigated in the BAL of infants with
early lung disease the cyanide levels were more closely
related to neutrophil number than to infection with
P. aeruginosa, presumably related to production via
neutrophil-derived thiocyanate [26].
The aim of the present study was to determine whether
YKL-40 reflected inflammation in the lungs in early CF
lung disease. We initially aimed to determine whether
YKL-40 was present in the BAL of infants and young chil-
dren with CF and whether YKL-40 levels related to
markers of inflammation. We next aimed to determine
whether YKL-40 could be detected in the serum and urine
of the same children and whether YKL-40 could be used
as a biomarker of inflammation in early CF lung disease.
Methods
Patient samples
Matched BAL, serum and urine samples were obtained
from 36 infants and young children with CF whoparticipated in the AREST CF early surveillance pro-
gram (ESP). Details of the program and collection of
biological samples have been described in detail else-
where [2,3,7,8,29]. Briefly, participants diagnosed with
CF via newborn screening were enrolled into the ESP.
At three months of age, and yearly thereafter around
the time of diagnosis, a series of procedures were per-
formed including: BAL for detection of inflammation
and infection; low dose CT scan for detection of struc-
tural abnormalities; and pulmonary function. At BAL,
three aliquots of saline (1ml per kilogram of body
weight) were instilled and retrieved from the right mid-
dle lobe. The first aliquot was used for microbiology
analysis, and aliquots two and three were pooled for
analyses of inflammation.
Methods for measuring cytokine concentrations, NE
activity, cell counts and detection of infection have been
described in detail previously (see online supplements in
[2,8]). Briefly, IL-8 was measured using an ELISA (BD
Opt EIA, BD Biosciences, San Diego, CA), other cytokines
were measured using a standard cytometric bead array hu-
man inflammation kit (BD Biosciences, San Diego, CA),
and free neutrophil elastase activity was measured using
an enzymatic assay. Pulmonary infection was determined
from BAL as previously described [30], with colony counts
of specific organisms (excluding mixed oral flora) ≥ 105
colony forming units /ml defined as pulmonary infection.
However, the presence of P. aeruginosa in any density in
BAL cultures was classed as infected.
The surveillance program was approved by the Prin-
cess Margaret Hospital for Children Ethics Committee
(EC00270) of Perth, Australia (Approval number 1762/
EP) and the Royal Children’s Hospital Human Research
Ethics Committee (EC00238) of Melbourne, Australia
(Approval number 25054), and conforms to the guide-
lines for conduct of research in children from the Na-
tional Health and Medical Research Council, Australia.
Informed consent was obtained from the parents of par-
ticipants at the time of BAL for collection and use of
participant samples.
Samples of BAL, serum and urine were drawn from
the AREST CF biobank if aliquots that had been col-
lected on the same occasion were available. Three
groups of samples were obtained based on the presence
of NE, and pulmonary infection with P. aeruginosa in
BAL; Group 1: no NE and no infection; Group 2: NE
present, no infection; Group 3: NE present, infection
with P. aeruginosa. The subjects contributing specimens
used in the present study were broadly representative of
the entire AREST CF cohort.
YKL-40
YKL-40 protein was measured in duplicate using a com-
mercial Human Chitinase 3-like 1 Quantikine ELISA Kit
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in matched BAL, sera and urine samples stored at -80°C.
The BAL and serum samples were diluted 1:500 and 1:50
in assay buffer. The urine samples were analysed neat.
The linear range of the assay was 50-4000 pg/ml.
C-Reactive protein (CRP)
CRP was measured in the same samples in duplicate
using a commercial kit AlphaLISA C-Reactive Protein
Research kit Cat AL233C AL233 C Lot No1658745
(PerkinElmer Inc. Waltham, Massachusetts, USA). The
linear dynamic range was from 30 pg/ml to 400,000 pg/ml.
Statistical analysis
Initially univariate analyses were conducted to determine
effects of age, gender, meconium ileus, pancreatic suffi-
ciency status, CF genotype and use of anti-staphylococcal
prophylaxis (with Augmentin®) on YKL-40 measures to
identify confounders. To account for the fact that individ-
ual patients could contribute more than one set of
samples to the analyses, associations between YKL-40, in
the BAL and serum, were compared with inflammatory
markers, infection and bronchiectasis score using a
random effects GLS regression analysis with a robust
standard error by patient ID on logged data. Analyses
were carried out using STATA, version 11 (StataCorp
LP, College Station, TX, USA).
Results
A total of 36 individual children contributed 55 unique
annual visits. BAL fluid was available at 54 visits, serum at
51 visits and urine at 50 visits. The demographics and
clinical features of the population are outlined in Table 1.
YKL-40 was detected in BAL and serum, although
levels in urine were below the limit of detection of the
assay in all samples. Levels in BAL [group median (IQR):
34.33 (71.38) ng/ml] were higher than in serum [group
median (IQR): 25.93 (16.78) ng/ml]. However, there were
no associations between concentrations of YKL-40 inTable 1 Demographic and clinical characteristics
Metric Variable




Pancreatic insufficient 33/36 (91.7%)
BAL1 Age at time of BAL (years)
[mean ± SD]
3.95 ± 2.21
Respiratory symptoms at time of BAL 22 (40%)
Respiratory infection in BAL 41 (75%)
P. aeruginosa infection in BAL 16 (29%)
155 BAL were obtained from 36 patients, variables related to each BAL
considered as a separate event.the BAL and YKL-40 in the serum using matched sam-
ples from the same individuals (r2 = 0.04, p = 0.138).
Levels of YKL-40 in BAL and serum were not associ-
ated with age at time of BAL, sex, initial presentation
with meconium ileus or regular antibiotic prophylaxis
(data not shown). Serum YKL-40, but not BAL YKL-40,
was higher in those with pancreatic insufficiency (β(SE):
0.44(0.08), p < 0.001), although the association was weak.
The number of children who were pancreatic insufficient
was very high (91.7%); therefore, pancreatic sufficiency
status was not included as a covariate in further ana-
lyses. Levels of YKL-40 in the BAL (p = 0.006), but not
serum (p = 0.43), were significantly increased in those
heterozygous for Phe508del compared to those homozy-
gous for Phe508del. There were no associations between
the presence of respiratory symptoms at the time of the
BAL and YKL-40 levels in BAL or serum (Table 2).
YKL-40 in BAL was significantly associated with most
inflammatory markers in BAL including number of mac-
rophages (r2 = 0.34, p < 0.001), number of neutrophils
(r2 = 0.74, p < 0.001) (Figure 1), NE (r2 = 0.47, p < 0.001),
CXCL8 (r2 = 0.45, p < 0.001) and IL-1β (r2 = 0.62, p < 0.001)
(Table 2). Concentrations of YKL-40 in BAL were higher
in the presence of any respiratory infection [β(SE): 1.30
(0.34), p < 0.001] and with infection with P. aeruginosa
[1.21(0.41), p = 0.003] (Figure 2). The associations between
YKL-40 in BAL and number of neutrophils (p < 0.001)
and IL-1β (p < 0.001) in BAL remained significant in a
multivariate analysis.
In contrast to YKL-40 in BAL, YKL-40 measured in
serum was not associated with pulmonary inflammation
or with overall infection status (Table 2). There was a
statistically significant, but weak (r2 = 0.06), association
between serum YKL-40 and pulmonary infection with
P. aeruginosa [0.33(0.15), p = 0.024] (Figure 2). Although
this association was not present after inclusion in a
multivariate model (p = 0.171). There were no associa-
tions between serum levels of YKL-40 and total or differ-
ential cell counts in blood (data not shown). Serum CRP
was measured as an indication of systemic inflammation.
Concentrations of CRP detected in this population were
all below the clinically significant cut-off value of 5 mg/L
[mean (sd): 0.07 (0.19) mg/L]. CRP levels were not asso-
ciated with levels of YKL-40 measured in serum (data
not shown).
Discussion
The data from the present study demonstrate that con-
centrations of YKL-40 in BAL, but not in the serum,
track with early indicators of lung disease in infants
and young children with CF. Specifically YKL-40 in
BAL reflects inflammation in the lungs, with positive
associations seen with: the number of neutrophils and
macrophages; concentration of NE; other markers of
Table 2 Associations between YKL-40 and pulmonary inflammation and infection
Variable YKL-40 in BAL YKL-40 in serum
β SE r2 p β SE r2 p
BAL macrophages (×103/ml fluid) 0.98 0.20 0.34 <0.001 0.10 0.11 0.02 0.34
BAL neutrophils (×103/ml fluid) 0.58 0.07 0.74 <0.001 −0.003 0.04 0.0002 0.92
NE (ng/ml) 0.45 0.06 0.47 <0.001 −0.02 0.04 0.004 0.61
CXCL8 (pg/ml) 0.49 0.07 0.45 <0.001 −0.03 0.05 0.01 0.55
IL-1β (pg/ml) 0.64 0.06 0.62 <0.001 0.08 0.04 0.04 0.052
IL-6 (pg/ml) 0.40 0.21 0.14 0.060 −0.03 0.08 0.005 0.69
Respiratory symptoms at BAL 0.36 0.40 0.06 0.366 −0.10 0.17 0.005 0.57
Pulmonary infection
• Any 1.30 0.34 0.17 <0.001 0.33 0.19 0.06 0.083
• P. aeruginosa 1.21 0.41 0.20 0.003 0.33 0.15 0.06 0.024
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and with infection, in particular with P. aeruginosa.
However, while YKL-40 was detectable in the serum of
children in CF, the serum levels did not correlate with
the BAL levels in the same patient nor with pulmonary
inflammation. YKL-40 was not detectable in urine. Col-
lectively, these findings indicate that YKL-40 in the
serum and urine do not reflect pulmonary infection
and inflammation, and therefore are not useful as a bio-
markers of early stage CF lung disease.
The positive associations between BAL levels of YKL-40
and indicators of active neutrophilic inflammation in the
lungs seen in the present study do suggest that YKL-40 is
likely to be of neutrophilic origin in early CF lung disease,
as suggested by previous in vitro cellular studies [13].
However, in contrast to previous reports in adults with CF
[10], the results of the present study show that YKL-40
concentrations in serum did not correlate with concen-
trations in BAL or with other markers of pulmonary
inflammation, infection or structural lung disease. ThisFigure 1 Relationship of number of neutrophils in bronchoalveolar
lavage (BAL) and YKL-40 in BAL (solid dots, solid line, r2 = 0.74,
p < 0.001) and YKL-40 in serum (open dots, non-significant).difference between children and adults may be due to the
different stage of pulmonary disease, particularly the se-
verity of neutrophilic airway inflammation, which in-
creases continuously from infant to adult CF lung disease.
We did confirm the lack of systemic inflammation by
low CRP levels in the serum of children in the present
study. In the study by Hector et al., it is possible that
either YKL-40 generated in the lungs “spilled over” into
the serum of their patients or that the serum levels
reflected systemic inflammation. Indeed other studies
have demonstrated increased levels of YKL-40 in the
blood in association with severe inflammation and sepsis
[31]. However, neither systemic inflammation, nor quan-
tities of YKL-40 “spilling over” into the serum appears to
be operative in the young children with CF we studied.
Association between serum levels of YKL-40 and the
presence of P. aeruginosa infection was weak butFigure 2 YKL-40 concentrations in BAL and serum related to
infection status, for those uninfected, infected with any organism
or infected with P aeruginosa. Note: the two infection groups are
not mutually exclusive. Statistical comparisons are between each of the
infected groups and the uninfected group. *Indicates the p-value of
comparison between infected with P. aeruginosa and not infected with
P. aeruginosa.
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model the association was no longer significant. YKL-40
is a marker of inflammation in both infectious and non-
infectious diseases, although due to associations with
inflammation and YKL-40 levels in non-infectious dis-
ease, it is likely YKL-40 is a reflection of inflammation
rather than bacterial load [18-20]. We have previously
reported increased inflammation with P. aeruginosa in-
fection in the lungs of paediatric patients with CF [30],
although other studies have reported no correlations
between lung and serum cytokine levels in CF, even
those chronically infected with P. aeruginosa [32,33].
However, the children in the present study do not have
chronic P. aeruginosa infection and increased YKL-40 or
other inflammatory markers in the blood of these pa-
tients due to P. aeruginosa infection seems unlikely. This
is verified as addition of the P. aeruginosa into a multi-
variate model reduced the significant associations be-
tween P. aeruginosa and YKL-40 levels in the serum.
We must caution that the sample size of the current
study is small, however, the inability to detect YKL-40 in
urine and the lack of associations between serum levels
of YKL-40 with those in BAL or with markers of pulmon-
ary inflammation in early life seriously question whether
larger studies are warranted in this age group.
While bronchoscopy and CT scans are used to detect
early changes in lung disease, these procedures cannot
be performed frequently and can only be performed
when children are well enough to undergo general an-
aesthesia. Biomarkers to identify early stage disease in
CF are important to monitor and track disease progres-
sion in the hope to stem progression. The AREST CF
program is ideally suited to the discovery and validation
of biomarkers of early lung disease. The simultaneous
collection and storage of BAL, serum and urine at 3
months of age and at annual reviews until 6 years of
age, together with extensive characterization of clinical
physiological and radiological aspects of early lung dis-
ease provide unique opportunities to examine the correl-
ation of proposed biomarkers. The group has previously
reported that serum antibodies against P. aeruginosa
were not predictive of P. aeruginosa grown in BAL [25]
and that the presence of cyanide in BAL was not predict-
ive of P. aeruginosa infection in early life [26]. The results
of the present study further demonstrate that biomarkers
that show promise in following CF disease severity in
older children and adults with established lung disease
must be validated in early life before being adopted.
Conclusions
In summary, while YKL-40 in BAL is reflective of
inflammation in early CF lung disease, it is not increased
in serum or urine in this age group and does not seem
to offer an advantage over measuring neutrophilicinflammation and NE activity directly. Further studies
are required to identify the pathophysiological role of the
chitinase-like protein in the pulmonary microenvironment
in CF lung disease.
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